M型磷脂酶A2受体在特发性膜性肾病中的临床应用
Clinical Application of M-Type Phospholipase A2 Receptor in Idiopathic Membranous Nephropathy
DOI: 10.12677/ACM.2023.132281, PDF,    科研立项经费支持
作者: 唐钰书：川北医学院附属南充市中心医院肾内科，四川 南充；谢席胜*：川北医学院附属南充市中心医院肾内科，四川 南充；慢性肾脏病基础与临床研究南充市重点实验室，四川 南充；南充市临床医学研究中心，四川 南充
关键词: 特发性膜性肾病；M型磷脂酶A2受体；临床应用；Idiopathic Membranous Nephropathy； M-Type Phospholipase A2 Receptor； Clinical Application
摘要: 特发性膜性肾病(Idiopathic membranous nephropathy, IMN)是一种常见的免疫性肾脏疾病，起病隐匿，临床表现复杂，并发症多，预后较差。经研究，M型磷脂酶A2受体被证实为成人IMN发病中的主要自身抗原，与70%~80% IMN有关，在IMN的诊断、治疗及预后评估中均体现出很高的参考价值。本文对M型磷脂酶A2受体的研究进展及临床应用进行综述。
Abstract: Idiopathic membranous nephropathy (IMN) is a common immune kidney disease with concealed onset, complex clinical manifestations, multiple complications and poor prognosis. Through re-search, M-type phospholipase A2 receptor has been confirmed to be the main auto antigen in the pathogenesis of adult IMN, and is related to 70%~80% IMN. It has high reference value in the diag-nosis, treatment and prognosis evaluation of IMN. This article reviews the research progress and clinical application of M-type phospholipase A2 receptor.
文章引用：唐钰书, 谢席胜. M型磷脂酶A2受体在特发性膜性肾病中的临床应用[J]. 临床医学进展, 2023, 13(2): 2018-2024. https://doi.org/10.12677/ACM.2023.132281

参考文献

[1] Tang, L., Yao, J., Kong, X., et al. (2017) Increasing Prevalence of Membranous Nephropathy in Patients with Primary Glomerular Diseases: A Cross-Sectional Study in China. Nephrology (Carlton), 22, 168-173. [Google Scholar] [CrossRef] [PubMed]
[2] Zhu, P., Zhou, F.D., Wang, S.X., et al. (2015) Increasing Frequency of Id-iopathic Membranous Nephropathy in Primary Glomerular Disease: A 10-Year Renal Biopsy Study from a Single Chi-nese Nephrology Centre. Nephrology (Carlton), 20, 560-566. [Google Scholar] [CrossRef] [PubMed]
[3] Brglez, V., Boyer-Suavet, S., Zorzi, K., et al. (2020) Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial. Frontiers in Medicine (Lausanne), 7, 412. [Google Scholar] [CrossRef] [PubMed]
[4] Ronco, P. and Debiec, H. (2015) Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Patient’s Care. The Lancet, 385, 1983-1992. [Google Scholar] [CrossRef] 
[5] Lai, W.L., Yeh, T.H., Chen, P.M., et al. (2015) Membranous Nephropathy: A Review on the Pathogenesis, Diagnosis, and Treatment. Journal of the Formosan Medical Association, 114, 102-111. [Google Scholar] [CrossRef] [PubMed]
[6] Ponticelli, C. and Glassock, R.J. (2014) Glomerular Diseases: Membranous Nephropathy—A Modern View. Clinical Journal of the American Society of Nephrology, 9, 609-616. [Google Scholar] [CrossRef] 
[7] Polanco, N., Gutiérrez, E., Covarsí, A., et al. (2010) Spontaneous Re-mission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 21, 697-704. [Google Scholar] [CrossRef] 
[8] 王蒙, 王力宁, 刘楠, 等. 血清抗PLA2R抗体水平对特发性膜性肾病的诊断及预后评估[J]. 中国实用内科杂志, 2020, 40(2): 153-157.
[9] Subramanyam, M. and Goyal, J. (2016) Translational Biomarkers: From Discovery and Development to Clinical Practice. Drug Discovery Today: Tech-nologies, 21-22, 3-10. [Google Scholar] [CrossRef] [PubMed]
[10] Beck, L.H., Bonegio, R.G., Lambeau, G., et al. (2009) M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. The New England Journal of Medicine, 361, 11-21. [Google Scholar] [CrossRef] 
[11] Hoxha, E., Kneißler, U., Stege, G., et al. (2012) Enhanced Expres-sion of the M-Type Phospholipase A2 Receptor in Glomeruli Correlates with Serum Receptor Antibodies in Primary Membranous Nephropathy. Kidney International, 82, 797-804. [Google Scholar] [CrossRef] [PubMed]
[12] Beck, L.H. and Salant, D.J. (2010) Membranous Nephropathy: Recent Travels and New Roads Ahead. Kidney International, 77, 765-770. [Google Scholar] [CrossRef] [PubMed]
[13] Ronco, P. and Debiec, H. (2014) Anti-Phospholipase A2 Recep-tor Antibodies and the Pathogenesis of Membranous Nephropathy. Nephron Clinical Practice, 128, 232-237. [Google Scholar] [CrossRef] [PubMed]
[14] Ronco, P., Plaisier, E. and Debiec, H. (2021) The Role of PLA2R Anti-body Monitoring: What We Know and What We Don’t Know. Nephrology Dialysis Transplantation, gfab356. [Google Scholar] [CrossRef] [PubMed]
[15] Kdigo (2021) Clinical Practice Guideline for the Management of Glomer-ular Diseases. Kidney International, 100, S1-S276. [Google Scholar] [CrossRef] [PubMed]
[16] Gunnarsson, I., Schlumberger, W. and Rönnelid, J. (2012) Antibodies to M-Type Phospholipase A2 Receptor (PLA2R) and Membranous Lupus Nephritis. American Journal of Kidney Diseases, 59, 585-586. [Google Scholar] [CrossRef] [PubMed]
[17] Garcia-Vives, E., Solé, C., Moliné, T., et al. (2019) Antibodies to M-Type Phospholipase A2 Receptor (PLA(2)R) in Membranous Lupus Nephritis. Lupus, 28, 396-405. [Google Scholar] [CrossRef] [PubMed]
[18] 张雅琪, 郝亚宁, 冯学亮, 等. 单中心特发性膜性肾病发病趋势及与血清PLA_2R抗体的相关性分析[J]. 中华肾脏病杂志, 2016, 32(9): 647-652.
[19] 庄永泽, 刘敏. 血清抗PLA2R抗体水平与成人特发性膜性肾病临床病理的相关性研究[J]. 中国中西医结合肾病杂志, 2019, 20(12): 1068-1072.
[20] Kim, Y.G., Choi, Y.W., Kim, S.Y., et al. (2015) Anti-Phospholipase A2 Receptor Antibody as Prog-nostic Indicator in Idiopathic Membranous Nephropathy. The American Journal of Nephrology, 42, 250-257. [Google Scholar] [CrossRef] [PubMed]
[21] Hoxha, E., Thiele, I., Zahner, G., et al. (2014) Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy. Journal of the American Soci-ety of Nephrology, 25, 1357-1366. [Google Scholar] [CrossRef] 
[22] Hofstra, J.M., Beck, L.H., Beck, D.M., et al. (2011) An-ti-Phospholipase A₂ Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 6, 1286-1291. [Google Scholar] [CrossRef] 
[23] Beck, L.H., Fervenza, F.C., Beck, D.M., et al. (2011) Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology, 22, 1543-1550. [Google Scholar] [CrossRef] 
[24] Segarra-Medrano, A., Jatem-Escalante, E., Carnicer-Cáceres, C., et al. (2014) Evolution of Antibody Titre against the M-Type Phospholipase A2 Receptor and Clinical Response in Idio-pathic Membranous Nephropathy Patients Treated with Tacrolimus. Nefrologia, 34, 491-497.
[25] Hoxha, E., Harendza, S., Zahner, G., et al. (2011) An Immunofluorescence Test for Phospholipase-A₂-Receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Glomerulonephritis. Nephrology Dialysis Transplantation, 26, 2526-2532. [Google Scholar] [CrossRef] [PubMed]
[26] Ruggenenti, P., Fervenza, F.C. and Remuzzi, G. (2017) Treatment of Membranous Nephropathy: Time for a Paradigm Shift. Nature Reviews Nephrology, 13, 563-579. [Google Scholar] [CrossRef] [PubMed]
[27] Seitz-Polski, B., Dolla, G., Payré, C., et al. (2016) Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. Journal of the American Society of Nephrology, 27, 1517-1533. [Google Scholar] [CrossRef] 
[28] Fresquet, M., Jowitt, T.A., Gummadova, J., et al. (2015) Identifica-tion of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 26, 302-313. [Google Scholar] [CrossRef] 
[29] Cremoni, M., Agbekodo, S., Teisseyre, M., et al. (2022) Toxic Occupational Exposures and Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 17, 1609-1619. [Google Scholar] [CrossRef] 
[30] Glassock, R.J. (2014) Antiphospholipase A2 Receptor Autoantibody Guided Diagnosis and Treatment of Membranous Nephropathy: A New Personalized Medical Approach. Clinical Journal of the American Society of Nephrology, 9, 1341-1343. [Google Scholar] [CrossRef] 
[31] Seitz-Polski, B., Dahan, K., Debiec, H., et al. (2019) High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 14, 1173-1182. [Google Scholar] [CrossRef] 
[32] Kanigicherla, D., Gummadova, J., Mckenzie, E.A., et al. (2013) An-ti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients with Idio-pathic Membranous Nephropathy. Kidney International, 83, 940-948. [Google Scholar] [CrossRef] [PubMed]
[33] Ruggenenti, P., Debiec, H., Ruggiero, B., et al. (2015) An-ti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology, 26, 2545-2558. [Google Scholar] [CrossRef] 
[34] Chen, Y., Schieppati, A., Cai, G., et al. (2013) Immunosuppression for Membranous Nephropathy: A Systematic Review and Meta-Analysis of 36 Clinical Trials. Clinical Journal of the American Society of Nephrology, 8, 787-796. [Google Scholar] [CrossRef] 
[35] Bech, A.P., Hofstra, J.M., Brenchley, P.E., et al. (2014) Association of Anti-PLA₂R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 9, 1386-1392. [Google Scholar] [CrossRef] 

为你推荐